9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Archive

Sodium Selenite as a Cytotoxic Agent in Advanced Carcinoma

Condition Malignant Tumor|Treatment Resistant Disorders|Tumor Progression Estimated Enrollment: 32 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: Eu-nr 2006-004076-13 Study First Received: October 8, 2013 Last Updated: October 8, 2013 Estimated Primary Completion Date: October 2016 Primary Outcome Measures: Maximal tolerable dose (phase I, ongoing)|Responses Sponsors and Collaborators: Karolinska University Hospital|Cancerfonden|Cancer and Allergy Foundation|Cancerföreningen i Stockholm|Stockholm County Council, Sweden Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT01959438...

Continue reading

An Audit of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

Condition Colorectal Cancer|Ovarian Cancer|Peritoneal Disease Estimated Enrollment: 150 Age Group: 18 Years to 70 Years   (Adult, Senior) Gender: All Study Type: Observational Study Design Allocation: Observational Model: Cohort|Time Perspective: Prospective Study ID Numbers: PN 1667 Study First Received: March 29, 2016 Last Updated: May 11, 2016 Estimated Primary Completion Date: April 2021 Primary Outcome Measures: Changes in invasive blood pressure in perioperative period|Changes in body temperature in perioperative period|Changes in cardiac output in perioperative period|Changes in arterial blood gas in perioperative period|Length of stay in intensive care unit|Mortality Sponsors and Collaborators: Tata Memorial Centre Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT02754115...

Continue reading

Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin

Condition Malignant Pleural Disease|Mesothelioma|Metastases|Lung Cancer|Breast Cancer Estimated Enrollment: 24 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment Study ID Numbers: 15-007 Study First Received: April 2, 2015 Last Updated: April 6, 2017 Estimated Primary Completion Date: April 2018 Primary Outcome Measures: Composite measure of severity and number of adverse events (AEs); changes in clinical laboratory test findings (hematologic and chemistry); and physical examination.|Changes in serum levels of the biomarker soluble mesothelin related peptide (SMRP) Sponsors and Collaborators: Memorial Sloan Kettering Cancer Center Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT02414269...

Continue reading

Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)

Condition Solid Tumors Estimated Enrollment: 1706 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: EMR 100070-001|2013-002834-19 Study First Received: January 14, 2013 Last Updated: December 22, 2016 Estimated Primary Completion Date: May 2018 Primary Outcome Measures: Dose Limiting Toxicity|Confirmed Best Overall Response (BOR) as per Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) for Efficacy Expansion Cohorts|Number of subjects with Treatment-Emergent Adverse Events according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.0|Pharmacokinetic parameters: AUC (0-t), AUC (0-infinity), λz, Cmax, Tmax, T(1/2) of avelumab|Immune-related Best...

Continue reading

A Study of BMS-986148 in Patients With Select Advanced Solid Tumors

Condition Advanced Cancer Estimated Enrollment: 407 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment Study ID Numbers: CA008-002|2014-002485-70 Study First Received: January 14, 2015 Last Updated: April 17, 2017 Estimated Primary Completion Date: April 2019 Primary Outcome Measures: Safety is measured by incidence of adverse events (AEs) at its worst grade, serious adverse events (SAEs) at its worst grade, adverse events leading to discontinuations, deaths, frequency of laboratory test toxicity grade shifting from baseline|Maximum observed serum or plasma concentration (Cmax) of BMS-986148|Time of maximum observed serum or plasma concentration (Tmax) of BMS-986148|Concentration at the...

Continue reading

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

Condition Solid Tumors|Triple-Negative Breast Cancer|Non Small Cell Lung Cancer|Renal Cell Carcinoma|Mesothelioma|Fumarate Hydratase (FH)-Deficient Tumors|Succinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumors (GIST)|Succinate Dehydrogenase (SDH)-Deficient Non-gastrointestinal Stromal Tumors|Tumors Harboring Isocitrate Dehydrogenase-1 (IDH1) and IDH2 Mutations|Tumors Harboring Amplifications in the cMyc Gene Estimated Enrollment: 205 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: CX-839-001 Study First Received: February 14, 2014 Last Updated: August 18, 2016 Estimated Primary Completion Date: June 2017 Primary Outcome Measures: Safety and tolerability of CB-839: Incidence of adverse events|Pharmacokinetics: Area under the Curve (AUC) of CB-839 concentration in blood|Pharmacodynamics: %...

Continue reading

αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies

Condition Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface|Malignant Peritoneal Mesothelioma|Peritoneal Carcinomatosis Estimated Enrollment: 168 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment Study ID Numbers: 12-110|5P01CA132714-05 Study First Received: May 28, 2014 Last Updated: February 2, 2017 Estimated Primary Completion Date: December 2017 Primary Outcome Measures: Number of participants with adverse events|Time to disease progression|How long participants live after surgery|Changes in the immune system Sponsors and Collaborators: Pawel Kalinski|National Cancer Institute (NCI)|University of Pittsburgh Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT02151448...

Continue reading

Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors

Condition Non-Small Cell Lung Cancer|Small Cell Lung Cancer|Extrapulmonary Small Cell Cancer|Pulmonary Neuroendocrine Tumors|Thymic Epithelial Tumors Estimated Enrollment: 2000 Age Group: 18 Years to 100 Years   (Adult, Senior) Gender: All Study Type: Observational Study Design Allocation: Observational Model: Cohort|Time Perspective: Prospective Study ID Numbers: 140105|14-C-0105 Study First Received: May 8, 2014 Last Updated: April 21, 2017 Estimated Primary Completion Date: April 30, 2024 Primary Outcome Measures: Allow sample acquisition for use in the study of thoracic malignancies except mesothelioma.|Follow the natural history of patients with thoracic malignancies.|Conduct genomic, proteomic and immunological analyses on blood, tumor, body fluid and normal tissue in support of NIH translational trials to develop new therapeutic agents and...

Continue reading

CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer

Condition Cervical Cancer|Pancreatic Cancer|Ovarian Cancer|Mesothelioma|Lung Cancer Estimated Enrollment: 136 Age Group: 18 Years to 70 Years   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Primary Purpose: Treatment Study ID Numbers: 120111|12-C-0111 Study First Received: April 20, 2012 Last Updated: April 20, 2017 Estimated Primary Completion Date: December 31, 2018 Primary Outcome Measures: Determine a safe dose of administration and determine if this approach will result in an objective tumor regression.|Determine the in vivo survival of CAR gene-engineered cells. Sponsors and Collaborators: National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT01583686...

Continue reading

A Study of Atezolizumab in Advanced Solid Tumors

Condition Solid Tumor Estimated Enrollment: 725 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment Study ID Numbers: MO29518|2015-000269-30 Study First Received: May 28, 2015 Last Updated: April 24, 2017 Estimated Primary Completion Date: November 29, 2018 Primary Outcome Measures: NPR: Percentage of Participants with CR, PR, or SD at 18 Weeks|NPR: Percentage of Participants with CR, PR, or SD at 24 weeks|Overall Response Rate (ORR): Percentage of Participants with CR or PR|Percentage of Participants by Best Overall Response (BOR)|Clinical Benefit Rate (CBR): Percentage of Participants with CR, PR, or SD Lasting for >/=6 Weeks|Duration...

Continue reading